BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 159749)

  • 1. [Increase of non-specific resistance to infection by synthetic adjuvants].
    Parant M; Chedid L
    C R Seances Soc Biol Fil; 1979; 173(2):201-12. PubMed ID: 159749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Synthesis and protective activity of beta-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine with alkylalicyclic and arylaliphatic aglycons].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2005; 31(6):637-44. PubMed ID: 16363137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic immunomodulators and synthetic vaccines.
    Leclerc C; Vogel FR
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):353-406. PubMed ID: 3103928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Potentiation of immune responses to influenza split virus vaccine by synthetic 6-O-acyl-muramylpeptides].
    Okunaga T
    Osaka Daigaku Shigaku Zasshi; 1980 Jun; 25(1):29-52. PubMed ID: 6935421
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant and antitumor activities of quinonyl-N-acetylmuramyldipeptides.
    Azuma I; Yamawaki M; Uemiya M; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Imada I; Yamamura Y
    Gan; 1979 Dec; 70(6):847-8. PubMed ID: 535688
    [No Abstract]   [Full Text] [Related]  

  • 6. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response.
    Lowy I; Theze J; Chedid L
    J Immunol; 1980 Jan; 124(1):100-4. PubMed ID: 6965289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide.
    Wahl SM; Wahl LM; McCarthy JB; Chedid L; Mergenhagen SE
    J Immunol; 1979 Jun; 122(6):2226-31. PubMed ID: 221582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of binding of MDP, a synthetic immunoadjuvant, to anti-peptidoglycan antibodies.
    Audibert F; Heymer B; Gros C; Schleifer KH; Seidl PH; Chedid L
    J Immunol; 1978 Oct; 121(4):1219-22. PubMed ID: 701793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fundamental studies to use the adjuvant activity of 6-o-acylmuramyldipeptides to potentiate cell and humoral immune responses for practical purposes].
    Tsujimoto M
    J Osaka Univ Dent Sch; 1981 Jun; 26(1):63-83. PubMed ID: 6945426
    [No Abstract]   [Full Text] [Related]  

  • 12. [Enhancement of resistance to microbial infection].
    Tamura M; Mameoka Y; Tsubura E
    Nihon Kyobu Shikkan Gakkai Zasshi; 1985 Feb; 23(2):171-5. PubMed ID: 3839543
    [No Abstract]   [Full Text] [Related]  

  • 13. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
    Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-specific MIF-like activity induced by the synthetic immunoadjuvant: N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).
    Adam A; Souvannavong V; Lederer E
    Biochem Biophys Res Commun; 1978 Nov; 85(2):684-90. PubMed ID: 367370
    [No Abstract]   [Full Text] [Related]  

  • 15. Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.
    Parant M; Chedid L
    Infection; 1984; 12(3):230-4. PubMed ID: 6469369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators.
    Audibert F; Chedid L
    Prog Clin Biol Res; 1980; 47():325-38. PubMed ID: 7010376
    [No Abstract]   [Full Text] [Related]  

  • 17. Specific impaired alloreactivity of mice immunized with syngeneic MLCT-lymphoblasts using muramylpeptides as adjuvant.
    Binz H; Tarcsay L; Wigzell H; Dukor P
    Transplant Proc; 1981 Mar; 13(1 Pt 1):566-73. PubMed ID: 6455801
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nor-MDP, saponin, corynebacteria, and pertussis organisms as immunological adjuvants in experimental malaria vaccination of macaques.
    Mitchell GH; Richards WH; Voller A; Dietrich FM; Dukor P
    Bull World Health Organ; 1979; 57 Suppl 1(Suppl):189-97. PubMed ID: 232428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP).
    Löwy I; Leclerc C; Bourgeois E; Chedid L
    J Immunol; 1980 Jan; 124(1):320-5. PubMed ID: 6985643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.